X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs ALKEM LABORATORIES - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA ALKEM LABORATORIES NATCO PHARMA/
ALKEM LABORATORIES
 
P/E (TTM) x 13.5 - - View Chart
P/BV x 3.9 6.5 59.6% View Chart
Dividend Yield % 1.2 0.7 172.4%  

Financials

 NATCO PHARMA   ALKEM LABORATORIES
EQUITY SHARE DATA
    NATCO PHARMA
Mar-18
ALKEM LABORATORIES
Mar-16
NATCO PHARMA/
ALKEM LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1,0801,589 68.0%   
Low Rs6711,232 54.5%   
Sales per share (Unadj.) Rs592.1417.5 141.8%  
Earnings per share (Unadj.) Rs188.456.3 334.7%  
Cash flow per share (Unadj.) Rs206.364.7 318.9%  
Dividends per share (Unadj.) Rs8.2512.70 65.0%  
Dividend yield (eoy) %0.90.9 104.6%  
Book value per share (Unadj.) Rs833.6292.9 284.6%  
Shares outstanding (eoy) m36.90119.57 30.9%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x1.53.4 43.8%   
Avg P/E ratio x4.625.1 18.6%  
P/CF ratio (eoy) x4.221.8 19.5%  
Price / Book Value ratio x1.14.8 21.8%  
Dividend payout %4.422.6 19.4%   
Avg Mkt Cap Rs m32,311168,653 19.2%   
No. of employees `0004.8NA-   
Total wages/salary Rs m3,2569,171 35.5%   
Avg. sales/employee Rs Th4,522.5NM-  
Avg. wages/employee Rs Th674.0NM-  
Avg. net profit/employee Rs Th1,439.0NM-  
INCOME DATA
Net Sales Rs m21,84849,915 43.8%  
Other income Rs m4041,645 24.6%   
Total revenues Rs m22,25251,561 43.2%   
Gross profit Rs m9,2848,482 109.5%  
Depreciation Rs m6621,006 65.8%   
Interest Rs m154671 23.0%   
Profit before tax Rs m8,8728,451 105.0%   
Minority Interest Rs m0-114 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,9201,606 119.6%   
Profit after tax Rs m6,9526,731 103.3%  
Gross profit margin %42.517.0 250.1%  
Effective tax rate %21.619.0 113.9%   
Net profit margin %31.813.5 236.0%  
BALANCE SHEET DATA
Current assets Rs m21,30727,062 78.7%   
Current liabilities Rs m5,92015,324 38.6%   
Net working cap to sales %70.423.5 299.5%  
Current ratio x3.61.8 203.8%  
Inventory Days Days7367 110.1%  
Debtors Days Days10741 258.0%  
Net fixed assets Rs m14,98612,610 118.8%   
Share capital Rs m369239 154.3%   
"Free" reserves Rs m30,35334,490 88.0%   
Net worth Rs m30,76035,027 87.8%   
Long term debt Rs m01,212 0.0%   
Total assets Rs m37,15154,387 68.3%  
Interest coverage x58.613.6 430.9%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.60.9 64.1%   
Return on assets %19.113.6 140.5%  
Return on equity %22.619.2 117.6%  
Return on capital %29.324.9 118.0%  
Exports to sales %012.9 0.0%   
Imports to sales %03.1 0.0%   
Exports (fob) Rs mNA6,461 0.0%   
Imports (cif) Rs mNA1,540 0.0%   
Fx inflow Rs m10,3226,563 157.3%   
Fx outflow Rs m2,9783,012 98.9%   
Net fx Rs m7,3433,552 206.8%   
CASH FLOW
From Operations Rs m4,6367,259 63.9%  
From Investments Rs m-11,1551,864 -598.4%  
From Financial Activity Rs m6,509-9,273 -70.2%  
Net Cashflow Rs m-18-150 12.0%  

Share Holding

Indian Promoters % 52.0 66.9 77.8%  
Foreign collaborators % 1.5 0.0 -  
Indian inst/Mut Fund % 7.8 33.1 23.7%  
FIIs % 16.6 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 0.0 -  
Shareholders   25,395 68,381 37.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   STRIDES PHARMA SCIENCE  AJANTA PHARMA  UNICHEM LAB  DR. DATSONS LABS  ELDER PHARMA  

Compare NATCO PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades 370 Points Up; Hero MotoCorp & Tata Motors Gain Over 5%(12:30 pm)

Stock markets in India are presently trading higher following the outcome of assembly polls announced on Tuesday.

Related Views on News

NATCO PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 115.2% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 115.2% YoY). Sales on the other hand came in at Rs 5 bn (up 27.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 93.3% YoY). Sales on the other hand came in at Rs 5 bn (up 21.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Dec 12, 2018 03:35 PM

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 5-YR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS